Stage IV Squamous Cell Lung Carcinoma AJCC v7 Recruiting Phase 2 / 3 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0092102 (Stage IV Squamous Cell Lung Carcinoma AJCC v7)Recruiting2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02154490Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerTreatment